MaxCyte, Inc. (MXCT) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for MaxCyte, Inc. (MXCT:NASDAQ), powered by AI.

Current Price
$1.12
P/E Ratio
-2.7
Market Cap
119M
Sector
Healthcare
What is the MaxCyte, Inc. stock price forecast?

MaxCyte, Inc. is currently trading at $1.12. View real-time AI analysis on Alpha Lenz.

What is MaxCyte, Inc. insider trading activity?

View the latest insider trading data for MaxCyte, Inc. on Alpha Lenz.

What is MaxCyte, Inc.'s P/E ratio?

MaxCyte, Inc.'s P/E ratio is -2.7.

MaxCyte, Inc.

NASDAQ · MXCT
$1.12+0.02(+1.82%)Pre-marketNASDAQ regular session 09:30–16:00 ET
Ask about MaxCyte, Inc.'s future dividend policy...
Alpha Chat Insight

MaxCyte, Inc. trades at a P/E of -2.7 (undervalued) with modest ROE of -23.6%.

Ask for details

Company Overview

MaxCyte Inc. is a biotechnology company that specializes in developing advanced cell engineering technology used across the biomedical industry. At the core of the company's operations is its proprietary electroporation platform, which enables precise, efficient, and scalable modifications of cells. This technology is pivotal for research and development in gene editing, cell therapy, and immune-oncology, fields that are rapidly evolving and gaining significance in the fight against various diseases, including cancer. MaxCyte Inc. provides tools and systems to pharmaceutical companies and research institutions, facilitating the development of novel therapeutics. Founded with a strong focus on innovation, the company plays a crucial role in advancing personalized medicine by supporting breakthroughs in genetic engineering. Its strategic collaborations and partnerships highlight its integral role in the biotechnology market, delivering cutting-edge solutions that address unmet medical needs and contributing to the progress of treatments affecting patients globally.

CEOMr. Maher Masoud
SectorHealthcare
IndustryMedical Devices
Employees114

Company Statistics

FY 2025

Profile

$119.20MMarket Cap
$33.03MRevenue
0.00Shares Out
114Employees

Margins

81.16%Gross
-101.53%EBITDA
-137.12%Operating
-135.14%Pre-Tax
-135.14%Net

Valuation

-2.67P/E
0.70P/B
3.61EV/Sales
-3.49EV/EBITDA
-3.29P/FCF

Growth (CAGR)

-9.30%Rev 3Yr
4.76%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-20.20%ROA
-23.63%ROE
-20.49%ROIC

Financial Health

$20.07MCash & Cash Equivalents
$10.95MNet Debt
18.09%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

MaxCyte, Inc. (ticker: MXCT) is a company listed on NASDAQ in the Healthcare sector (Medical Devices). It has approximately 114 employees. Market cap is $119M.

The current price is $1.12 with a P/E ratio of -2.67x and P/B of 0.7x.

ROE is -23.63% and operating margin is -137.12%. Annual revenue is $33M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
MaxCyte, Inc. (MXCT) Stock Forecast 2026 $1.12 — Price, Financials & Analyst Targets | Alpha Lenz